

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/590,551	08/24/2006	Hong-Gil Nam	1012679-000127	6706	
21839 7590 LIMBAZDOR BUCHANAN, INGERSOLL & ROONEY PC POST OFFICE BOX 1404			EXAM	EXAMINER	
			BAUM, STUART F		
ALEXANDRIA, VA 22313-1404		ART UNIT	PAPER NUMBER		
			1638		
			NOTIFICATION DATE	DELIVERY MODE	
			11/03/2008	EL ECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

ADIPFDD@bipc.com

Application No. Applicant(s) 10/590,551 NAM ET AL. Office Action Summary Examiner Art Unit STUART F. BAUM 1638 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 24 August 2006. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 1-20 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date _

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (FTO/SE/08)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date. ______.

Other: sequence search result.

5) Notice of Informal Patent Application

Application/Control Number: 10/590,551 Page 2

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 and 18, drawn to an isolated polypeptide and a method of producing a protein.

Group II, claim(s) 2-9 and 14, drawn to an isolated polynucleotide; a recombinant vector, cell, method and plant comprising said polynucleotide.

If Applicants elect Group II, Applicants are also to elect one sequence from the list below:

SEQ ID NO:4 SEQ ID NO:14

Group III, claim(s) 10-13 and 19, drawn to a method for producing a dwarf plant comprising inserting a polynucleotide encoding the sequence of amino acids 1-138 of SEQ ID NO:4 into a plant; and plant produced by said method.

Group IV, claim(s) 15 and 17, drawn to a method of identifying a phytochrome signal transduction-associated substance.

Application/Control Number: 10/590,551 Page 3

Art Unit: 1638

Group V, claim(s) 16 and 20, drawn to a method of identifying a plant dwarfism-causing substance.

- 2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the isolated polypeptide having an amino acid sequence set forth in SEQ ID NO:4 is taught in the prior art. The Office interprets "an amino acid sequence set forth in SEQ ID NO:14" to encompass a multitude of sequences because of the article "an". Luo et al (2003, U.S. Patent 6,660,511 B1) teach an amino acid sequence of SEQ ID NO:2 that exhibits 60% identity to Applicants' SEQ ID NO:14 (sequence search results attached) and comprises an amino acid sequence set forth in SEO ID NO:14.
- 3. In addition, the claims are not linked by a single technical feature because they are each drawn to products and processes not shared by the other. The purified polypeptide and variants thereof of Group II are not shared by the nucleic acid molecule of Group II which is not shared by the methods of Groups III-V.
- Each of Inventions I-V are capable of being separately made, independently used and the patentability of one does not render the others obvious or unpatentable.

Art Unit: 1638

5. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by the literature and sequence searches required for each of the Inventions are not required for another of the Inventions, restriction for examination purposes as indicated is proper.

- Applicant is advised that the reply to this requirement to be complete must include an
 election of the invention to be examined even though the requirement be traversed (37
 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart F. Baum whose telephone number is 571-272-0792. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

/Stuart F. Baum/ Stuart F. Baum Ph.D. Primary Examiner Art Unit 1638 October 27, 2008